The partnership is focused on advancing out-licensing opportunities for DosePro, with a focus on co-marketing the technology to potential biopharmaceutical and government clients.
DosePro is marketed by the both the companies using the ‘Less is More’ campaign, which emphasizes the simplicity and benefits of the DosePro technology and its ability to provide instantaneous, needle-free, subcutaneous drug delivery.
The campaign highlights a study by Battelle that demonstrates the ability of the DosePro system to effectively deliver a monoclonal antibody therapeutic, AbbVie’s Humira (adalimumab).
The in vitro study showed that DosePro can deliver Humira without incremental risk to protein denaturation and equivalent biological integrity as compared to delivery by pre-filled syringe.
Battelle process and product development vice president and general manager William Dunlevy said over the course of the past year the company has worked with Zogenix to develop and implement a focused co-marketing campaign which highlights key attributes of the DosePro needle-free delivery system.
"We have received positive feedback regarding our study of DosePro delivery of a monoclonal antibody and our self-injection survey of patients with rheumatoid arthritis. These findings clearly demonstrate the benefits and capabilities of the DosePro system," Dunlevy added.
"This has driven strong interest in the DosePro technology from our clients, particularly in the delivery of highly viscous formulations and biologics."
